OncoMatch/Clinical Trials/NCT05423262
A Study of TRK-950 in Patients With Advanced Solid Tumors
Is NCT05423262 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies multiple treatments for solid tumor.
Treatment: TRK-950 · TRK-950 · TRK-950 · Nivolumab · TRK-950 — Part 1 • To determine the safety and tolerability of TRK-950 in patients with advanced solid tumors Part 2 • To determine the safety and tolerability of TRK-950 in combination with nivolumab(NIVO) in patients with advanced solid tumors eligible for NIVO therapy Part 3 • To determine the efficacy of TRK-950 in patients with advanced/recurrent unresectable melanoma, who received prior chemotherapy with dacarbazine(DTIC) and for whom no standard therapy exists
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Other
Cancer type
Tumor Agnostic
Melanoma
Prior therapy
Must have received: chemotherapy (dtic)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05423262 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received chemotherapy.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages